Skip to main content
Premium Trial:

Request an Annual Quote

IP Watch: MDxHealth, GSK, Ambergen, Keygene, Bio-Rad, Illumina Among US Patent Winners

Premium

MDxHealth and GlaxoSmithKline Biologicals, both of Belgium, have been awarded US Patent No. 8,481,700, "Detection of MAGE-A expression."

Ilse Vlassenbroeck and Katja Bierau are named as inventors.

Describes an oligonucleotide, primer, or probe comprising specific nucleotide sequences further described in the patent. The oligonucleotides are useful for the detection of the methylation status of a gene, in particular the MAGE-A3 gene. The oligonucleotides are useful in primer pairs, kits, and methods for determining the methylation status of the MAGE-A3 gene and for diagnosing cancer, directing therapy, and selecting subjects for treatment. The primer or probe can comprise a loop or hairpin structure and can be used in real-time methylation-specific PCR.


AmberGen has been awarded US Patent No. 8,481,263, 'Bead-ligand-nascent protein complexes."

Mark Lim and Kenneth Rothschild are named as inventors.

Describes bead-ligand-nascent protein complexes, and a method of creating and detecting the complexes. PCR-amplified product attached to a surface, e.g. of a bead, is used to generate nascent protein, which in turn is captured on the bead and detected, e.g. by fluorescence.


Postech Academy-Industry Foundation and Catholic University Industry-Academic Cooperation Foundation, both of South Korea, have been awarded US Patent No. 8,481,261, "Nucleic acid extraction method."

Relates to a nucleic acid extracting apparatus, which can include a pipe-shaped tube having an open outlet at one side thereof, and a hydrogel column that is located inside the tube and filters impurities excluding an extraction target material.


Keygene of Wageningen, The Netherlands, has been awarded US Patent No. 8,481,257, "Method for high-throughput AFLP-based polymorphism detection."

Michael Van Eijk, Anker Sorensen, and Marco Van Schriek are named as inventors.

Relates to a method for the high-throughput discovery, detection, and genotyping of one or more genetic markers in one or more samples. The method comprises the steps of restriction endonuclease digest of DNA, adaptor-ligation, optional pre-amplification, selective amplification, pooling of the amplified products, sequencing the libraries with sufficient redundancy, clustering followed by identification of the genetic markers within the library and/or between libraries, and determination of (co-)dominant genotypes of the genetic markers, the patent's abstract states.


The Wistar Institute and the University of Pennsylvania have been awarded US Patent No. 8,476,420, "Method for diagnosing lung cancers using gene expression profiles in peripheral blood mononuclear cells."

Michael Showe, Louise Showe, Malik Yousef, Steven Albelda, Anil Vachani, and Andrei Kossenkov are named as inventors.

Provides methods and compositions for diagnosing lung cancer in a mammalian subject by use of three or more selected genes, e.g., a gene expression profile, from the peripheral blood mononuclear cells of the subject that is characteristic of disease, a stage of the disease, or enables prognosis of recurrence of disease. The gene expression profile includes three or more genes described in greater detail in the patent. The method involves detecting changes in expression in the selected genes from that of a reference gene expression profile and correlating these changes with non-small cell lung cancer. One composition for use in such diagnosis includes three or more PCR primer-probe sets, wherein each primer-probe set amplifies a different polynucleotide sequence from the gene expression profile. Another composition for similar use contains a plurality of polynucleotides immobilized on a substrate, which hybridize to three or more gene expression products from genes in the gene expression profile. Still another composition involves detection of the protein expression products of genes from the gene expression profile.


Bio-Rad Laboratories has been awarded US Patent No. 8,476,045, "Methods of using improved polymerases."

Yan Wang, Peter Vander Horn, and Lei Xi are named as inventors.

Provides methods of sequencing and performing polymerase reactions using an improved generation of nucleic acid polymerases. The improvement is the fusion of a sequence-non-specific nucleic acid-binding domain to the enzyme in a manner that enhances the processivity of the polymerase, the patent's abstract states.


Illumina has been awarded US Patent No. 8,476,044, "Method of nucleic acid amplification."

Pascal Mayer, Laurent Farinelli, and Eric Kawashima are named as inventors.

A nucleic acid molecule can be annealed to an appropriate immobilized primer. The primer can then be extended and the molecule and the primer can be separated from one another. The extended primer can then be annealed to another immobilized primer and the other primer can be extended. Both extended primers can then be separated from one another and can be used to provide further extended primers. The process can be repeated to provide amplified, immobilized nucleic acid molecules. These can be used for many different purposes, including sequencing, screening, diagnosis, in situ nucleic acid synthesis, monitoring gene expression, nucleic acid fingerprinting, et cetera, the patent's abstract states.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.